%0 Journal Article
%T Midazolam Indications and Dosing in Palliative Medicine: Results from a Multinational Survey.
%A Tranung M
%A Solheim TS
%A Løhre ET
%A Marsaa K
%A Faksvåg Haugen D
%A Laird B
%A Thronæs M
%A Due Larsen M
%J Curr Oncol
%V 31
%N 7
%D 2024 Jul 19
%M 39057177
%F 3.109
%R 10.3390/curroncol31070305
%X Despite sparse evidence and limited guidance on indications, use, and dosing, midazolam is widely used in palliative care. We aimed to describe and compare the use of midazolam in three different countries to improve clinical practice in palliative care. We performed an online survey among palliative care physicians in Norway, Denmark, and the United Kingdom (UK). The focus was indications, dosing, administration, and concomitant drugs. A web-based questionnaire was distributed to members of the respective national palliative medicine associations. The total response rate was 9.4%. Practices in the UK, Norway, and Denmark were overall similar regarding the indications of midazolam for anxiety, dyspnoea, and pain treatment in combination with opioids. However, physicians in the UK used a higher starting dose for anxiety, dyspnoea, and pain treatment compared to Norway and Denmark, as well as a higher maximum dose. Danish physicians preferred, to a higher degree, on-demand midazolam administration. Despite practice similarities in the UK, Norway, and Denmark, differences exist for midazolam dosing and administration in palliative medicine. We demonstrated a lack of consensus on how midazolam should be used in palliative care, setting the stage for future studies on the topic.